Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cancer’s Spread has a Head Start, Making it Difficult to Stop, Research Says

October 30, 2015 8:30 am | by Seth Augenstein, Digital Reporter | News | Comments

Cancer has a molecular head start in the body long before doctors can detect a tumor, according to new research. The disease essentially “seeds” the body with metastatic cells by using a kind of cheating molecule, known as epidermal growth factor receptor (EGFR) to clear its pathway, long before a tumor can be detected, according to the study, in the journal Neoplasia. Read more...


Natural Immunity May Lead Fight Against Liver Disease

October 30, 2015 8:15 am | by University of Adelaide | News | Comments

Researchers have uncovered the role played by a family of genes, which can suppress hepatitis C virus infection within the liver. Read more...


Key Findings to Develop Vaccine Against Toxoplasma

October 30, 2015 8:05 am | by Osaka University | News | Comments

Using experimental animals such as mice, basic research for developing an inactivated vaccine is underway. Read more...


Possible New Explanation for ALS

October 30, 2015 8:00 am | by University of Toronto | News | Comments

Many cases of ALS are sparked by a toxic build-up of certain proteins. Read more...

Blockbuster Drugs will Push Multiple Myeloma Treatment Market to $22.4B by 2023

October 30, 2015 7:45 am | by Dan Roberts, Ph.D., Senior Oncology & Hematology Analyst, GlobalData | News | Comments

The patent expiries of a number of key treatments will pave the way for the new mAbs to have a major impact on the multiple myeloma therapeutics space by 2023. Read more...


Pfizer, Allergan in Talks for Tentative Blockbuster Merger

October 29, 2015 12:42 pm | by Ryan Bushey, Associate Editor | News | Comments

Allergan said these talks are still in the very early stages. Read more...


Nanotechnology Could Spur New Heart Treatment

October 29, 2015 10:17 am | by University of Michigan | News | Comments

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke. Read more...


$20M Commonwealth Foundation for Cancer Research Gift to Expand Collaborative Cancer Research

October 29, 2015 10:05 am | by MIT | News | Comments

The Commonwealth Foundation for Cancer Research has pledged $20 million to the Bridge Project, a collaborative research program of the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC), to accelerate the translation of interdisciplinary cancer solutions toward the clinic. Read more...


New Enzyme Therapy Shows Proof of Concept as Treatment for Cocaine Overdose

October 29, 2015 10:00 am | by American Association of Pharmaceutical Scientists (AAPS) | News | Comments

A long-acting enzyme that rapidly and safely metabolizes cocaine in the blood stream is currently being investigated in animal models as a possible treatment for cocaine overdose. Read more...


Sanofi Recalls All Injectors Used for Allergic Reactions

October 29, 2015 9:56 am | by Associated Press | News | Comments

Sanofi is recalling hundreds of thousands of epinephrine injectors used to treat severe allergic reactions because they may not deliver the correct amount of the life-saving drug. Read more...


AAPS 2015: 3-D Printing's Potential for Drug Development

October 29, 2015 9:20 am | by Ryan Bushey, Associate Editor | News | Comments

The Association of American Pharmaceutical Scientists (AAPS) annual meeting in Orlando, Florida kicked off Tuesday with an early morning discussion highlighting new advances in the 3-D printing field. Read more...


Physiologic Progesterone Not Associated with Breast Cancer in WHI Trial

October 29, 2015 8:30 am | by Cynthia Fox, Science Editor | Articles | Comments

A prominent editorial, finding breast cancers arose in the massive 16,000-patient Women’s Health Initiative (WHI) study due to “progesterone,” is outright wrong, wrote a top gynecologist and a top oncologist in a recent JAMA Oncology. Read more....


Boehringer Ingelheim’s Biosimilar Candidate: Phase I Study Results

October 28, 2015 4:02 pm | News | Comments

​Boehringer Ingelheim announced results from a Phase I study of its biosimilar candidate for adalimumab (AbbVie’s Humira), that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. Read more...


Retroviral RNA May Play a Part in Liver Cancer

October 28, 2015 3:55 pm | by RIKEN | News | Comments

An international group led by RIKEN in Japan and INSERM in France have found that retroviral long-terminal-repeat (LTR) promoters—a type of repetitive element that are widely distributed in the human genome—are highly activated in hepatocellular carcinomas, the most common type of liver cancer. Read more...


Astellas Inititaties Phase 3 Registration Trial of Gilteritinib in Relapsed or Refractory AML

October 28, 2015 3:43 pm | News | Comments

Astellas Pharma Inc. yesterday announced dosing of the first patient in a randomized Phase 3 registration trial of gilteritinib (ASP2215) versus salvage chemotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The primary endpoint of the trial is overall survival (OS). Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.